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Medline, PubMed, and EMBASE to identify full economic evaluations that com-
pared different treatment strategies in postmenopausal women with primary 
breast cancer. Quality and modelling methodologies of included studies were 
assessed and summarised. Results: All the 31 included studies assessed surgery 
and none assessed PET as the initial treatment. Most included economic stud-
ies used a Markov model with life-time horizon and 1-year cycle length. Nine 
studies which included sub-group analysis for older women (over 65 years old) 
used similar economic models and transition states with younger women (50 
to 65 years old). The key disease-related health states were disease-free, recur-
rence, and death. Recurrence was mostly separated into loco-regional and distant 
recurrence. ConClusions: This systematic review can inform the design of an 
economic model comparing PET with surgery as initial treatment in older women 
based on the following assumptions: (1) health states are applicable across age 
groups; (2) transition states for modelling surgery in the literature are transferable 
to model the same treatment for older women; (3) metastasis transition states 
including progression, progression-free, and death can be used to model the PET 
pathway. Future study will validate this model by using a longitudinal dataset of 
older women with primary breast cancer, and synthesize data from different data 
sources to populate this economic model.
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objeCtives: Colorectal cancer is the third most common cancer in Scotland, with 
nearly 4,000 cases reported in 2011 and 5.2% increase in incidence in the previous 
10 years. Recent studies have shown that a subgroup of metastatic colorectal cancer 
(mCRC) patients with wild-type (wt) RAS (KRAS and NRAS exons 2,3, 4) expressing 
tumours are likely to have enhanced response to anti-EGFR treatment compared 
to patients with mutant RAS exons (2,3, 4). RAS biomarkers aid identification of the 
patient group that is likely to benefit the most from anti-EGFR treatment such as 
cetuximab and therefore allow more efficient use of NHS Scotland resources. A New 
Product Assessment Form was submitted to the Scottish Medicines Consortium with 
the aim of demonstrating the latest improved outcomes in RAS wt mCRC patients 
(versus KRAS wt) treated with cetuximab in combination with chemotherapy and 
its cost effectiveness compared to currently available treatments. Methods: 
A state-transition Markov cohort model was developed to simulate patient outcomes 
and costs for first and subsequent lines of treatment including the long-term sur-
vival after a successful curative resection of liver metastases. Results: The model 
estimated an incremental 0.28 life-years gained (LYG) with cetuximab + FOLFIRI 
compared to FOLFIRI alone and an incremental 0.32 LYG with cetuximab + FOLFOX 
compared to FOLFOX alone. The model was most sensitive to length of treatment 
with cetuximab. ConClusions: The incremental cost effectiveness ratios imputed 
in the model are close to the traditional willingness to pay threshold adopted by 
the SMC. This analysis demonstrates that cetuximab in combination with FOLFIRI 
or FOLFOX in mCRC RAS wt patients is a cost-effective treatment compared with 
chemotherapy alone, specifically when taking into consideration that cetuximab 
qualifies as an end of life medicine (following SMC criteria) which raises the value 
of such intervention.
PCN140
Cost-EffECtivENEss aNaLysis of bEvaCizumab, fotEmustiNE 
aNd ExtENdEd-dosE tEmozoLomidE iN PatiENts With rECurrENt 
GLiobLastoma iN sPaiN
Garcia Lopez J.L.1, Rodriguez Barrios J.M.2, Puig-Junoy J.2, Carrato Mena A.1
1Ramon Y Cajal University Hospital, Alcala University, Madrid, Spain, 2Pompeu Fabra University, 
Barcelona, Spain
The treatment of glioblastoma after first-line treatment progression is not clearly 
established in Spain. Most accepted alternatives are nitrosoureas (fotemustine, F), 
extended-dose temozolomide (eT) or bevacizumab (B). Without clear standards of 
care, increased clinical and health policy uncertainty among decision makers should 
be clarified. So, economic evaluation might reduce those uncertainties. objeCtives: 
To analyze the cost-effectiveness of bevacizumab, extended-dose temozolomide 
and fotemustine in patients with either recurrent or progressive glioblastoma after 
standard therapy, compared to standard clinical practice (SCP). Methods: A cost-
effectiveness markov model was conducted from a payer perspective (time horizon 
1 year, 3%, discount rate, 2012, € ). Our model got three health states: alive without 
progression, alive with toxicity and progression as absorbing state. We subsequently 
performed a deterministic and probabilistic analysis of sensitivity. Main efficacy 
outcome was progression-free survival at six months (6m PFS). Toxicity data was 
based on relevant phase II studies. Health state utility values were estimated based 
on published values from an HTA report by Garside et al, 2007. Costs were obtained 
from a Spanish University Hospital. Results: Cost/effectiveness ratios were: SCP 
(based on carmustine) 2,368.45 € /year to obtain 6m PFS with stable health state 
utility value, F 4,112.97 € /year, B 15,122.49 € /year and eT 5,470.05 € /year. Incremental 
cost-effectiveness ratios were: F 7,404.12 € /year € /year to obtain 6m PFS with stable 
health state utility value, B 40,371.8 € /year and eT 45,853.51 € /year. Tornado diagram 
and CEAC showed our results robustness. ConClusions: ICER analysis shows fote-
mustine to be the dominant option in the treatment of patients with recurrent or 
progressive glioblastoma.
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from each taxpayer. ConClusions: A cancer cure evaluated under current health 
economic evaluation methods would cause a budget impact that would be 
unaffordable for governments due to the high prices that could be achieved 
while remaining cost effective. Although these types of technologies therapies 
are not currently available, payers might want to explore new methods of evalu-
ation, as exploring the possibility of calculating costs based on quality adjusted 
lifetimes rather than years or increasing discount rates on QALYs for immuno-
therapies.
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objeCtives: To analyze the economic impact of the incorporation of pertuzumab 
for the treatment of metastatic breast cancer HER2+ in a University Hospital accord-
ing to real data of our patients. Methods: Cross-sectional study where the patients 
with breast cancer were analyzed in our hospital during one year (April 2013 to 
April 2014). The demographic data of the patients (age and weight) and antineo-
plastic treatments used were obtained from the computer program Hospiwin®. 
The dose and efficacy data have been obtained from the phase III CLEOPATRA trial. 
This clinical trial compares docetaxel + trastuzumab vs docetaxel + trastuzumab + 
pertuzumab with progression-free survival (PFS) 12.4 (CI 10.4-13.5) vs. 18.5 (CI 16.6-
21.6) months respectively. Costs of the drugs were included in the economic model 
developed in Excel® data base. The time horizon was one year and the perspective 
of medical leadership of the hospital was used. Results: During the study period 
371 patients were treated for breast cancer and 75 patients (20.2 %) were HER2+. The 
mean weight of 71.5 kg (SD = 17.1) and men BMI of 29.3 were obtained. The annual 
cost of docetaxel + trastuzumab + pertuzumab was 69,245.32 € vs 29,837.4 € (CI (in 
the docetaxel + trastuzumab treatment group. The cost per PFS per year was 44,964 
€ (CI 38,469-50,177 € ) in the docetaxel + trastuzumab + pertuzumab group vs 29,837 
(CI 26,640-35,948 € ) in the docetaxel + trastuzumab treatment group. The incremen-
tal cost effectiveness ratio (ICER) was 15.127 € /PFS per year. ConClusions: The 
addition of pertuzumab to treatment with docetaxel / trastuzumab for metastatic 
breast cancer has shown an increase in SLP. However, the economic impact of this 
new drug, requires careful selection of patients who could benefit. Health authori-
ties will have to consider whether pertuzumab is cost-effective in terms of their 
willgness to pay.
PCN136
Cost EffECtivENEss of suNitiNib as first-LiNE tarGEtEd thEraPy for 
mEtastatiC rENaL CELL CarCiNoma iN ChiNa
Shi Q.1, Yin H.2, Xuan J.3, Wu Y.4, Cheng G.5
1Pfizer China, Shanghai, China, 2Philadelphia College of Osteopathic Medicine-Georgia Campus, 
Suwanee, GA, USA, 3Fudan University, School of Public Health, Shanghai, China, 4Foshan food 
and drug inspection testing center, Foshan City, China, 5Jinan University, Guangzhou, China
objeCtives: Multitargeted receptor tyrosine kinase inhibitors are more effec-
tive alternatives to interferon-α and monoclonal antibodies in patients with 
metastatic renal cell carcinoma (mRCC). However, studies on the economic and 
humanistic outcomes associated with these treatments are sparse in the Chinese 
setting. This study evaluated the clinical and economic consequences of sunitinib 
compared with sorafenib and interferon-α from the third-party payer’s perspective 
in China. Methods: A Markov model was developed to simulate disease progres-
sion and determine cost and outcomes over patient’s lifetime. The time horizon 
of analysis was patients’ lifetime with a maximum of five years in cycles of six 
weeks. The model was used to conduct a cost-utility analysis on sunitinib compared 
to interferon-α and sorafinib. Costs of physician, anti-cancer medications, hospi-
talization, laboratory, and palliative care were estimated. Outcomes were meas-
ured in progression-free life years (PFLYs), life years (LYs) and quality-adjusted life 
years (QALYs). A 3.5% discount rate was applied to both costs and QALYs gained.  
Results: In the base case, the total cost of the sunitinib arm was RMB217,038.50, 
the progression-free life year was 1.57, life year was 2.55, and QALY was 1.70. The 
incremental cost per PFLY between sunitnib and IFN-α was –RMB78,562.10 and 
RMB 22,501.03 between sunitinib and sorafenib. The incremental cost per life year 
between sunitnib and IFN-α was –RMB168,633.00 and RMB 21,022.38 between suni-
tinib and sorafenib. The incremental cost per QALY between sunitnib and IFN-α was –
RMB184,825.00 and RMB 29,493.42 between sunitinib and sorafenib. ConClusions: 
This economic study used the final clinical results of the pivotal sunitinib trial that 
provides more accurate modeling results than previous studies based on extrapola-
tion. It was found that sunitinib was dominant compared to IFN-α . Sunitinib was 
cost effective compared to sorafenib based on the threshold recommended by the 
World Health Organization.
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objeCtives: Despite the lack of evidence-based information on their clinical and 
cost-effectiveness, surgery and primary endocrine therapy (PET) are the most 
commonly used initial treatment strategies for older women with primary breast 
cancer in the United Kingdom (UK). To evaluate the cost-effectiveness of PET and 
surgery, a decision analytical modelling is necessary. This systematic review aimed 
to summarise the modelling methodologies from the literature to inform the 
model design in older women. Methods: An electronic database search was 
conducted using NHS Economic Evaluation Database, Cochrane Library, Ovid 
